Pharmafile Logo

M3 announces further expansion into Europe and Latin America with the acquisition of Vidal Group

December 3, 2016 |  

M3 is strengthening and growing its global operations with the acquisition of Vidal Group, a trusted provider of prescribing information and clinical decision support services to doctors and other HCPs in key markets including France, Germany, Spain and Latin America. This move complements M3’s existing business activities in Japan, the United States, United Kingdom, China, Korea and India.

Since the first publication of its pharmaceutical information encyclopaedia in 1914, the Vidal brand has gained powerful recognition amongst doctors, HCPs and the general public across French speaking countries.Additionally, Vidal’s brands such as Gelbe Liste and MMI Pharmindex in Germany and Vidal Vademecum in Spain,Central and South America, are well-renowned within their respective markets.
Vidal is recognised as the most trusted information source by physicians in France (n=388, June 2015) and has reach to over 290,000 doctors andmany other health care professionals in Europe and Latin America.
Vidal provides a very comprehensive multimedia suite of services with prescribing information and clinical decision support to enable doctors, pharmacists and other HCPs to deliver better patient care through the optimal use of medicines and therapeutics and the adoption of new advances in medical knowledge.
Through this acquisition, M3 plans to support the continued growth of Vidal’s existing services across Europe and Latin America and to expand the range of services provided to healthcare by leveraging M3’s experience and expertise in other markets including market research, digital communications, clinical trials and recruitment services.
Aki Tomaru, Board Director and CEO of M3 USA commented “The addition of the Vidal Group to M3 marks a very significant and important step for M3 in its mission to deliver trusted and high quality medical information and services in key markets across the world to drive forward innovation, improved efficiency and better outcomes in healthcare.”

About M3:
M3 operates in Asia, the US and Europe with more than 4 million physician doctor members globally via M3.com,MDLinx, Medigate, medlive.cn, M3Medical and Doctors.net.uk. Ranked 5th on Forbes’ Most Innovative Growth Companies in 2016, M3 provides a wide range of healthcare services across clinical trials, pharmaceutical marketing, research services, educational programmes, patient information and physician recruitment services.More information and contacts:For more information on the acquisition of the Vidal Group by M3 please contact Hannah Brown on +44 (0)7747273879 or hannah.brown@eu.m3.com.For more information on M3 visit http://www.m3.com or http://eu.m3.com

This content was provided by M3 (EU)

Company Details

 Latest Content from  M3 (EU) 

Tailored and Targeted Pharmaceutical Marketing

Learn more about targeted personas for HCP marketing.    If pharma companies want to differentiate themselves against their competition and produce impactful results they must be much bolder than the current state...

Learning to invest in doctors’ education

Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for...

Engaging doctors around the globe

Embedding a digital strategy as a prominent part of a pharmaceutical marketing campaign is becoming ever more important. Despite some perceived reluctance on the part of the industry, pharmaceutical companies...

How do doctors spend their time online?

In our recent research piece, Doctor networks: The rules of engagement for pharma, some overarching principles for online engagement between the pharmaceutical industry and doctors were defined.

How do doctors want to engage with pharma on new products?

More than 80% of European doctors agree they are interested in staying up-to-date with new developments about pharmaceutical products. But what influences their choice of treatment and how do they...

M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a website provider...

Revolutionising the Digital Content Delivery Model

Pharmaceutical industry processes don’t have to make the delivery of marketing campaigns slow and unmanageable, and thus ineffective. Changing working practices and really, truly thinking differently about how to deliver...

Healthcare in the Digital Age

Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship.

M3 announces further expansion into Europe and Latin America with the acquisition of Vidal Group

M3 is strengthening and growing its global operations with the acquisition of Vidal Group, a trusted provider of prescribing information and clinical decision support services to doctors and other HCPs...

UK's department of Health deploys information campaign to ensure continued vigilance over Ebola

The threat of Ebola being transmitted within the UK may be low but frontline health workers must remain vigilant nevertheless. This is the message being communicated by the Department of...